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Background: Muscle-invasive bladder cancer (MIBC) can be cured by radical radiotherapy (RT). We previously found
tumour MRE11 expression to be predictive of survival following RT in MIBC, and this was independently validated in a
separate institute. Here, we investigated germline MRE11A variants as possible predictors of RT outcomes in MIBC,
using next-generation sequencing (NGS).
Patients and methods: The MRE11A gene was amplified in germline DNA from 186 prospectively recruited MIBC
patients treated with RT and sequenced using bar-coded multiplexed NGS. Germline variants were analysed for associa-
tions with cancer-specific survival (CSS). For validation as a prognostic or predictive marker, rs1805363 was then geno-
typed in a cystectomy-treated MIBC cohort of 256 individuals. MRE11A mRNA isoform expression was measured in
bladder cancer cell lines and primary tumour samples.
Results: Carriage of at least one of six (five novel) rare variants was associated with the worse RT outcome (hazard ratio
[HR] 4.04, 95% confidence interval [95% CI] 1.42–11.51, P = 0.009). The single-nucleotide polymorphism (SNP),
rs1805363 (minor allele frequency 11%), was also associated with worse CSS (per-allele HR 2.10, 95% CI 1.34–3.28,
Ptrend = 0.001) following RT in MIBC, with a gene-dosage effect observed, but no effect seen on CSS in the cystectomy
cohort (Ptrend = 0.89). Furthermore, rs1805363 influenced relative MRE11A isoform expression, with increased isoform 2
expression with carriage of the rs1805363 minor A allele.
Conclusions: GermlineMRE11A SNP rs1805363 was predictive of RT, but not of cystectomy outcome in MIBC. If suc-
cessfully validated in an independent RT-treated cohort, this SNP could be a useful clinical tool for selecting patients for
bladder-conserving treatment.
Key words:MRE11A, bladder cancer, next-generation sequencing, radiotherapy, cystectomy, biomarkers
introduction
Muscle-invasive bladder cancer (MIBC) is the sixth most
common cause of male cancer death in the UK (http://info.
cancerresearchuk.org/cancerstats/type/bladder). Radical radio-
therapy (RT) and chemoradiotherapy (CRT) have the advantage
over cystectomy of bladder preservation, with similar cure rates in
selected patients [1, 2]. With the failure of a recent trial randomis-
ing cystectomy versus RT (SPARE) [3], there is an urgent need to
find a predictive biomarker to aid treatment choice in MIBC.
MRE11, as part of the MRE11–RAD50–NBS1 complex,
detects and binds to DNA double-strand breaks (DSBs), the
lethal lesions caused by RT, processes damaged DNA ends and
activates the ATM protein, cell cycle checkpoints and apoptot-
ic responses [4]. In MIBC, we found tumour MRE11 protein
expression to be predictive of survival following RT but not
cystectomy [5, 6]. Germline single-nucleotide polymorphisms
(SNPs) in DNA damage response genes, including MRE11A,
have been associated with an increased bladder cancer risk
[7, 8]. Candidate gene studies have found associations
with RT response in several cancer sites, and in MIBC
coding ERCC2 and XRCC1 SNPs were associated with plat-
inum-based CRT outcomes [9]. Acute and late normal tissue
toxicity following RT has also been studied, including at the
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genome-wide level, but these initial candidate SNP hits have
not yet been replicated [10].
There is a high negative selection pressure against coding var-
iants of MRE11A; dbSNP (http://www.ncbi.nlm.nih.gov/snp/)
contains only nine non-synonymous coding variants, all rare
with minor allele frequencies (MAFs) <1%. Rare germline var-
iants are more likely to be functional than the more common
SNPs; they can only be detected by DNA sequencing, made af-
fordable by next-generation sequencing (NGS) technology [11].
We hypothesised that NGS could identify germline SNPs and
rare variants in MRE11A predictive of both tumour response
and toxicity following radical RT in MIBC.
methods
patients
MIBC RT patients (N = 201) were recruited prospectively having given
written informed consent with local ethical approval, as previously described
[2, 12] and treated using three-dimensional conformal external beam RT
(52.5–55 Gy in 20 fractions over 4 weeks) between August 2002 and October
2009 in Leeds, UK. Toxicity data were collected as outlined in supplementary
Methods and supplementary Table S9, available at Annals of Oncology
online. Blood samples were collected before RT and germline DNA extracted
using standard salting-out protocols. Cystectomy patients (N = 256) were
treated at Aarhus University Hospital, Denmark, between 1992 and 2008
[13] without neoadjuvant or adjuvant chemotherapy. Time of death was pro-
vided by the Danish Central Personal Registry and cause of death by hospital
charts.
germline MRE11A sequencing, sequence analysis,
variant calling and genotyping
The MRE11A reference genomic sequence (NCBI Accession NG_007261.1
HG19 assembly accessed January 2011, size 76.6 kb) was used. For each RT-
treated MIBC individual, all exons plus flanking introns (minimum 200
bases) were amplified as long PCR products in 12 amplicons (total 28.2 kb)
(supplementary Table S1, available at Annals of Oncology online), then nor-
malised in equimolar quantities. Tagged library preparation was carried out
as previously described [14] using an unique indexed adaptor for each indi-
vidual (supplementary Table S2, available at Annals of Oncology online).
Twenty to 24 indexed libraries were pooled together in equimolar quantities
and each pool was single-end sequenced for 90 cycles on an Illumina GAII.
In-house software (Illuminator) [15] was used for indexed read sorting and
sequence alignment against the reference MRE11A genomic sequence, and
variants called if coverage was >200× and the variant allele seen in >20% of
reads. Poor confidence ‘variants’ were excluded by visual inspection of se-
quence alignment and read coverage data. High-confidence variants were
confirmed by conventional Sanger sequencing (supplementary Table S3,
available at Annals of Oncology online). In the cystectomy cohort, rs1805363
was genotyped using standard pre-designed Taqman SNP genotyping assays
(Applied Biosystems, UK).
MRE11A mRNA isoform expression profiling
MRE11A isoforms were amplified using primers flanking MRE11A
rs1805363 and conventionally Sanger sequenced (see supplementary File 1,
available at Annals of Oncology online).
statistical analysis
Cancer-specific survival (CSS) analysis was carried out using Kaplan–Meier
and Cox proportional hazard models for all confirmed SNPs and rare
variants. Assuming an overall 50% 5-year CSS, at a 5% significance level, the
RT-treated MIBC cohort had >80% power to detect a hazard ratio (HR) of
2.00 for an MAF of 0.20 and >85% for a HR of 3.00 at an MAF of 0.05 (see
supplementary File 1, available at Annals of Oncology online).
results
MIBC patient demographics
At 76-month median follow-up (range 20.3–104.6 months), there
were 70 cancer-specific events in the 186 RT-treated MIBC
patients where PCR amplification was successful. Clinical details
of the cystectomy-treatedMIBC cohort (N = 256) have been previ-
ously published [13] (Table 1). No patient had distant metastases.
MRE11A variants identified from next-generation
sequencing
RT patient samples were sequenced in nine pools, with 2507×
median coverage per sample (range 673–9891); 95% of target
regions were sequenced at over 221× per sample. Following
filtering for high-confidence variants, 85 variants were selected
for confirmatory sequencing and were all successfully validated
(supplementary Table S4, available at Annals of Oncology
online). Thirty of 33 common SNPs (MAF >0.05) were in high
linkage disequilibrium with each other (R2 > 0.80, data not
shown); nine common haplotypes were seen (supplementary
Figure S1, available at Annals of Oncology online).
genetic associations with survival in the RT-treated
MIBC cohort
In Cox proportional hazards analysis, none of the demographi-
cal and histological/clinico-pathological variables were signifi-
cantly associated with CSS (Table 2), perhaps reflecting the
sample size and relative variable frequencies. Using the data-
adaptive sum test, collapsed analysis of the uncommon and rare
variants (MAF <0.05) did not reveal any significant associations
with CSS for all the rare variants (P = 0.45) or just rare exonic
variants (P = 0.59). As the 30 UTR is involved in gene post-tran-
scriptional regulation and hence could influence MRE11 expres-
sion, we carried out simple collapsed analysis of the six rare
MRE11 30 UTR variants seen in seven individuals. Carriage of at
least one 30 UTR rare variant was significantly associated with
worse CSS (P = 0.009; Table 2) in carriers versus non-carriers
(5-year CSS: 42.9% versus 54.8%, respectively; Figure 1A).
Individual variant analysis identified two common SNPs to
be significantly associated with CSS, rs1805363 (Ptrend = 0.001)
and rs13447623 (Ptrend = 0.05) (Table 2), with the respective
variant A and G alleles in complete linkage disequilibrium
(D0 = 1.00, R2 = 0.38). A two-locus model of both SNPs showed
that only rs1805363 was significant, indicating that the effect
seen with the rs13447623 G allele was secondary to concomitant
carriage of the rs1805363 A allele. The rs1805363 A minor allele
was associated with worse CSS following RT treatment (per-
allele HR 2.10, 95% confidence interval [95% CI] 1.34–3.28,
P trend = 0.001), and a gene-dosage effect was seen: GG 5-year
CSS 58.3%, GA 42.0% and AA 0% (Figure 1B). No significant
interaction was detected between rs1805363 and baseline
prognostic factors, again possibly due to insufficient power.
Corrections for multiple testing were not carried out. For a
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simple Bonferroni correction, the significance threshold would
be 6 × 10−4, making rs1805363 non-significant. However, this
correction would be over-conservative, not accounting for the
extensive linkage disequilibrium in the region. A haplotype ana-
lysis (supplementary Figure S1, available at Annals of Oncology
online) results in a Bonferroni significance threshold of 0.006
with a significant association for the only haplotype containing
rs1805363 (P-value unchanged). Carriage of the rs1805363 A
allele and 30 UTR rare variants was mutually exclusive.
genetic associations with late radiation
bladder toxicity
Thirty-four patients developed ≥Grade 2 CTC bladder toxicity
and three developed ≥Grade 2 CTC late rectal toxicity. Neither
the 30 UTR rare variants nor rs1805363 were associated with
developing late bladder toxicity (P = 0.09 and 0.33, respectively).
Rare variants were not associated with toxicity on collapsed ana-
lysis. However, rs13447623 and the common 30 UTR SNP
rs2155209 (MAF = 0.38) [7] were associated with late bladder
toxicity (per-allele odds ratio [OR] 2.12, 95% CI 1.30–3.45,
Ptrend = 0.003; and per-allele OR 0.57, 95% CI 0.35–0.92,
Ptrend = 0.02, respectively); only rs13447623 contributed inde-
pendently to bladder toxicity risk on conditional analysis
(P = 0.03). There was no association seen between severity of
acute radiation bladder toxicity and late radiation bladder tox-
icity (N = 134, P = 0.33) or of rs13447623 with severity of acute
radiation bladder toxicity (P = 0.41, supplementary Table S5,
available at Annals of Oncology online).
rs1805363: prognostic versus predictive marker
To explore the prognostic versus predictive value of rs1805363
on MIBC CSS, 256 MIBC patients treated by radical cystectomy
were genotyped for rs1805363. No association was found
between the rs1805363 genotypes and CSS (per-allele HR 0.99,
95% CI 0.61–1.60, Ptrend = 0.89); GG 5-year CSS of 59.7%, GA
54.0% and AA 75.0% (Figure 1C). Multivariate analysis, adjust-
ing for age, gender, tumour stage, nodal stage and histological
grade, did not reveal any significant associations of the
rs1805363 genotypes with CSS (P = 0.88). This suggests that
MRE11 is functionally involved in the RT response (i.e. predict-
ive) rather than a general prognostic marker in MIBC.
rs1805363 influences MRE11A isoform expression
rs1805363’s location is either intronic in MRE11A isoform 1,
five bases 30 to the Exon 1 AG donor splice site, or within the
50 UTR of MRE11A isoform 2 (Figure 2A). We hypothesised
that rs1805363 may influence gene splicing and/or relative
isoform expression. Tumour RNA was obtained from pre-treat-
ment samples in three RT-cohort patients, one AA and two GA,
and six wild-type bladder cancer cell lines (supplementary
Figure S2, available at Annals of Oncology online). The relative
expression of MRE11A isoform 1 (139 bp) and isoform 2 (246
bp) was determined (Figure 2B). There was no difference in
overall MRE11A expression between genotypes (supplementary
Table S6, available at Annals of Oncology online), and the per-
centage of MRE11A isoform 1 relative to overall MRE11A fell
with each rs1805363 minor A allele (GG 61.7%, GA 49.6% and
AA 30.3%). The isoforms were confirmed on sequencing (sup-
plementary Figure S3, available at Annals of Oncology online).
rs1805363 and tumour MRE11 protein expression
MRE11 immunohistochemical protein expression data were
available in 72 RT patients [5]. There was no evidence of signifi-
cant correlation between the number of rs1805363 A alleles
carried or 30 UTR rare variants and a tumour MRE11 semi-
quantitative score (P = 0.48 and 0.61, respectively; supplemen-
tary Table S7, available at Annals of Oncology online).
Table 1. Clinical demographics of the MIBC study cohorts
Variable RT-treated cohort
(N = 186), n (%)
Cystectomy-treated
cohort (N = 256), n (%)
Age (years)
Median (range) 79 (55–93) 65 (34–85)
Gender
Male 139 (74.7) 187 (73.0)
Female 47 (25.3) 69 (27.0)
Tumour stagea
T2 118 (63.5) 94 (36.7)
T3 51 (27.5) 112 (47.6)
T4 9 (4.9) 40 (15.7)
Tx 8 (4.4) 0 (0.0)
Nodal stage
N0 179 (96.3) 184 (71.9)
N1 4 (2.2) 32 (12.5)
N2+ 2 (1.1) 39 (15.2)
Nx 1 (0.6) 1 (0.4)
Histological grade
High grade 167 (89.8) 251 (98.0)
Low grade 14 (7.6) 5 (2.0)
Unrecorded 5 (2.7) 0 (0.0)
Hydronephrosis
No 135 (72.6) Data not available
Yes 51 (27.5) Data not available
Neoadjuvant chemotherapy
Not received 175 (94.1) 256 (100.0)
Received 11 (6)b 0 (0.0)
Concurrent chemotherapy/radiosensitizer
Not received 171 (91.9) 256 (100.0)
Received 15 (8.1)c 0 (0.0)
Salvage/adjuvant chemotherapyc
Not received 177 (95.2) 256 (100.0)
Received 9 (4.9) 0 (0.0)
Salvage cystectomy
Not received 167 (89.8) Not applicable
Received 19 (10.3) Not applicable
aTumour stage in the RT-treated cohort was the highest of the pre-
treatment biopsy and radiological stage; in the cystectomy-treated
cohort, the highest of the pre-treatment biopsy and post-cystectomy
pathological stage.
bAll received platinum-based combination chemotherapy.
cTen patients received concurrent gemcitabine (100 mg/m2) weekly
×4 as part of a phase II clinical trial and five patients received
concurrent carbogen and nicotinamide as part of the BCON
phase III clinical trial.
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discussion
Predictive biomarkers are clearly needed to aid clinical decision-
making in MIBC, but radiogenetics remains in its infancy
despite successes in pharmacogenetics.
MRE11A has a key role in DNA DSB detection and repair sig-
nalling, with low tumour MRE11 protein expression predictive
of worse RT outcome in MIBC patients [5, 6]. Ricceri et al. [16]
identified five intronic MRE11A SNPs significantly associated
with increased DSB repair efficiency, in peripheral blood mono-
nuclear cells from 118 healthy individuals. We thus looked for
MRE11A genetic variants associated with tumour response and
radiation toxicity. Previous radiogenetics studies on RT clinical
outcomes have focused on candidate coding DNA repair gene
SNPs. Although a candidate gene approach was used here, NGS
technology allowed in-depth investigation of all MRE11A var-
iants in the study population, including novel rare ones, rather
than only known variants or tag SNPs.
We found, for the first time, germline MRE11A SNPs and
rare variants associated with survival and late radiation normal
tissue toxicity following RT in MIBC. MRE11A 30 UTR rare
variant carrier status and the common SNP rs1805363 were
associated with poor RT outcomes, and rs13447623 with
increased late radiation bladder toxicity, thus potentially identi-
fying patients not best served by bladder-conserving RT treat-
ment. In cystectomy-treated patients, rs1805363 was not
associated with prognosis, suggesting that it is a predictive
genetic RT marker in MIBC. From dbSNP (http://www.ncbi.
nlm.nih.gov/projects/SNP), 20% of the European population
carry at least one allele of this SNP. In our RT and cystectomy
cohorts, 18.2% and 15.5% carried at least one allele, respectively.
The SNP could have significant clinical impact in identifying RT
poor responders, with homozygous carriers doing particularly
badly (all dead within 24 months).
No published data are available on the relative expression or
functional differences between the two expressed isoforms of
MRE11A transcripts (http://genome.ucsc.edu/): isoform 1 (4772
bases: shorter 50 UTR and exon 16 expressed) and isoform 2
(4668 bases: longer 50 UTR and exon 16 not expressed). We
hypothesised that rs1805363 could influence isoform expression
as it was situated only five bases from the isoform 1 30 terminal
of exon 1. Expression was reduced with each minor allele
carried. Isoform 2 may result in more efficient DSB repair thus
promoting cancer cell survival, or isoform 1 may be critical for
initiating DSB repair and cell death pathways, thus reduction
in isoform 1 results in failure of cancer cells to initiate apoptosis
after RT. Alternatively, as the MRN complex exists as a heterote-
tramer containing two MRE11 molecules [4], a critical balance
of isoforms may be required for complex stability or DSB
detection.
There was no evidence of correlation between rs1805363
genotype and MRE11 protein expression, so its effects may be
mediated at the mRNA level.
To our knowledge, this is the first study investigating an asso-
ciation between germline rare variants and RT outcomes. We
identified one known and five novel rare variants in the 30 UTR
of MRE11A (supplementary Table S8, available at Annals of
Oncology online), associated with survival following RT
(Figure 1A). Only one of these six rare variants was predicted to
Table 2. Cox proportional hazards multivariate analysis of cancer-specific survival in demographical, histological/clinic-pathological variables, and in
rs1805363, rs13447623 and 30 UTR rare variants
Covariates HR (95% CI) P-valuea
Age at diagnosis (years) 1.01 (0.98–1.04) 0.61
Gender (male versus female) 0.72 (0.39–1.31) 0.28
T stage (increasing stage) 1.50 (0.98–2.30) 0.06
N stage (increasing stage) 1.96 (0.88–4.37) 0.10
Histological grade (increasing grade) 1.12 (0.50–2.48) 0.79
Hydronephrosis (yes versus no) 1.21 (0.66–2.22) 0.53
Neoadjuvant/concurrent chemotherapy (yes versus no) 0.52 (0.22–1.20) 0.12
Variant (observed MAF) Genotype N
rs1805363 G > A (0.11) GG 152 1 0.001
AG 28 1.49 (0.80–2.78)
AA 6 8.00 (2.93–21.90)
rs13447623 A > G (0.25) AA 110 1 0.05
AG 62 0.86 (0.50–1.49)
GG 14 3.68 (1.78–7.60)
Joint two-SNP analysis
rs1805363 G > A 2.19 (1.12–4.30) 0.02
rs13447623 A > G 0.95 (0.54–1.66) 0.86
Rare variants collapsed analysis
No 30 UTR rare variants 179 1 0.009
1+ 30 UTR rare variants 7 4.04 (1.42–11.51)
aSignificant P-values of <0.05 are in bold.
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affect microRNA binding (supplementary Table S8, available at
Annals of Oncology online).
This study demonstrates the first use of NGS technology for
the in-depth investigation of germline common and rare var-
iants within a candidate gene for potential biomarkers of RT
outcomes. To our knowledge, only four other studies, in haem-
atological malignancies, have applied NGS technology to search
for potential prognostic biomarkers [17–20]. With rapid
advances in NGS technology, larger studies are now possible,
thus accelerating the discovery of new predictive and prognostic
biomarkers [21, 22], and diagnostic laboratories already use
NGS technology for clinical genetic testing. Also, whole-genome
sequencing can be carried out on germline DNA and tumour
DNA, and the first reports in bladder cancer are eagerly awaited.
Germline genetic SNP markers have several advantages over
tumour immunohistochemistry markers: a blood sample is
easily obtainable for DNA extraction, SNP genotyping is rapid,
so patient treatment is not delayed and the result is clearly
binary (SNP present/absent).
The main limitations of this study were the relatively small
sample sizes and the lack of an available independent RT-
treated MIBC validation study population. Whether rs1805363
is a true predictive marker of RT response still needs to be vali-
dated in a second independent cohort. Unfortunately, none of
the recent or on-going phase III RT clinical trials in bladder
cancer collected germline DNA samples for translational re-
search [3, 23, 24], which must be seen as a research priority. We
cannot tell if neoadjuvant chemotherapy treatment or concur-
rent chemotherapy/radiosensitisers would influence the predict-
ive value of the MRE11A variants, but our previous RT-alone
MRE11 immunohistochemistry findings were subsequently vali-
dated in a CRT cohort [5, 6].
In summary, using NGS technology for the first time in
MIBC, we have identified germlineMRE11A SNPs and rare var-
iants as potential markers of RT outcomes and toxicity in
MIBC. Carriage of MRE11A rs1805363A was predictive of poor
RT outcomes but not surgery in MIBC patients and was shown
to affect relativeMRE11A isoform expression. Further validation
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Figure 1. Kaplan–Meier graphs of (A) cancer-specific survival (CSS) for carriers of at least one 30 UTR MRE11A rare variant allele in the RT-treated MIBC
cohort; (B) CSS for MRE11A rs1805363 genotypes in the RT-treated MIBC cohort and (C) CSS for MRE11A rs1805363 genotypes in the cystectomy-treated
MIBC cohort.
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of rs1805363 is urgently needed for its translation into clinical
practice as a predictive tool for personalised medicine.
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Do quality of life or physical function at diagnosis
predict short-term outcomes during intensive
chemotherapy in AML?
N. Timilshina1, H. Breunis1, J. M. Brandwein2, M. D. Minden3, V. Gupta3,
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Background: Intensive chemotherapy (IC) used to treat acute myeloid leukemia (AML) is associated with toxicity,
particularly in older adults. Emerging data suggest that baseline quality of life (QOL) and physical function may predict
outcomes in oncology, although data in AML are limited. We investigated the association between baseline QOL and
physical function with short-term treatment outcomes in adults and elderly AML patients.
Materials and methods:We conducted a prospective, longitudinal study of adults (age 18+) AML patients undergoing
IC. Before starting IC, patients completed the European Organisation for the Research and Treatment of Cancer (EORTC)
30-item questionnaire (QLQ-C30) and Functional Assessment of Cancer Therapy Fatigue subscale (FACT-Fatigue) in
addition to physical function tests (grip strength, timed chair stands, 2-min walk test). Outcomes included 60-day mortal-
ity, intensive care unit (ICU) admission and achievement of complete remission (CR). Logistic regression was carried out
to evaluate each outcome.
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